1785EGP
- Active ingredient
- insulin glargine+lixisenatide
- Strength
- 33 mcg/ml
- Form
- tablet
- Manufacturer
- sanofi
- Route
- oral.solid
Uses
Used with diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Do not use if
Hypoglycemia and serious hypersensitivity to insulin glargine, lixisenatide, or any component.
Side effects
Common adverse effects include hypoglycemia, nausea, vomiting, diarrhea, and injection-site reactions.
Warnings
Monitor for pancreatitis, severe allergic reactions, dehydration, and hypoglycemia.
How it works
Combines a long-acting basal insulin with a GLP-1 receptor agonist to improve blood glucose control.
Storage
Store refrigerated at 2–8°C before first use. Do not freeze.